This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) closed the most recent trading day at $0.68, moving -1.93% from the previous trading session.
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
by Zacks Equity Research
Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Bellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $7.65, marking a +1.06% move from the previous day.
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) closed at $10.04 in the latest trading session, marking a -0.4% move from the prior day.
Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) closed the most recent trading day at $9.92, moving -0.6% from the previous trading session.
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) closed the most recent trading day at $10.98, moving -1.08% from the previous trading session.
Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus
by Zacks Equity Research
Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength Amid March Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.
Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
by Zacks Equity Research
Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.
Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Faster adoption of digital health and improved business environment are expected to have contributed to Walgreens' (WBA) third-quarter performance.
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
by Zacks Equity Research
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
by Zacks Equity Research
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
by Zacks Equity Research
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
by Zacks Equity Research
Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
by Zacks Equity Research
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Company News for May 12, 2020
by Zacks Equity Research
Companies In The News Are:
Company News for Mar 23, 2020
by Zacks Equity Research
Companies In The News Are: BLPH, GNMK, WORK, SRNE